OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M

OPKO HEALTH, INC.

2025-Q3 EPS reported -$0.26 revenue$458,429,000

Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.
Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.
Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.
Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.